585 related articles for article (PubMed ID: 18725232)
1. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
2. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
3. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
5. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
6. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
[TBL] [Abstract][Full Text] [Related]
7. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
[TBL] [Abstract][Full Text] [Related]
8. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix.
Liu F; Chen Z; Wang J; Shao X; Cui Z; Yang C; Zhu Z; Xiong D
Neoplasia; 2008 Nov; 10(11):1275-84. PubMed ID: 18953437
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
Su Y; Lee SH; Sinko PJ
Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
[TBL] [Abstract][Full Text] [Related]
11. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Stein U; Scheffer GL; Lage H
Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
[TBL] [Abstract][Full Text] [Related]
14. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
16. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Elahian F; Kalalinia F; Behravan J
Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
[TBL] [Abstract][Full Text] [Related]
18. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
19. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
[TBL] [Abstract][Full Text] [Related]
20. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
